Tissue Acquisition, Processing, and Pathology (TAPP) Core

组织采集、处理和病理学 (TAPP) 核心

• 批准号: 8566678
• 负责人: MICHAEL D KALOS
• 金额: $ 12.06万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8566678
• 关键词: Anatomy; Antigens; Archives; Biological Assay; Biological Markers; Cell Line; Cessation of life; Chest; Clinical; Clinical Trials; Diagnosis; Enrollment; Goals; Ice; Instruction; Interferon-alpha; Interferons; Malignant Neoplasms; Neoplasm Antibodies; Operative Surgical Procedures; Pathologic; Pathologist; Pathology; Pathology processes; Patients; Process; Role; Sampling; Serological; Serum; Specimen; Specimen Handling; Tissues; Tumor Antigens; Tumor-Derived; immuno-gene therapy; mesothelin; neutralizing antibody; stable cell line; tumor

PROJECT SUMMARY (See instructions): The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are: A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens. B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1). C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1) D. Tissue acquisition (with Projects 1, 2 and 3). E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3). F. Assist in immunohistochemical analyses Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.

项目摘要（请参阅说明）： 组织获取，俯冲和病理学核心的目标是： A.审查和分析临床试验患者的病理标本（项目1），包括表达间皮素水平和潜在的其他肿瘤抗原。 B.正在进行和计划的临床试验（项目1）的过程和档案临床标本。 C进行干扰素-α，抗腺病毒中和抗体，血清间皮素和抗肿瘤抗体的测定法（项目1） D.组织采集（项目1、2和3）。 E.从临床试验受试者和其他外科患者（项目1、2和3）中得出的肿瘤中建立稳定的细胞系。 F.协助免疫组织化学分析 迈克尔·卡洛斯（Michael Kalos）博士将担任Tapp Core的主任，因为Carroll博士不幸去世。董事会认证的解剖病理学家莱斯利·利兹基（Leslie Litzky）博士将重点关注目标A，并继续担任指定参考病理学家的角色，以确认诊断临床试验，并在临床试验中进行诊断，并在肿瘤样品中审查中皮素或其他抗原表达。史蒂文·阿尔贝尔达博士 执行修订目标C（以前确定的血清学测定）和E（细胞系建立）所需的专业知识将有助于这一核心。